These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 7081135)

  • 1. Multiple myeloma: a therapeutic enigma.
    Hoogstraten B
    Am J Clin Oncol; 1982 Feb; 5(1):13-9. PubMed ID: 7081135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New aspects in the clinical course determination and therapy in multiple myeloma].
    Ludwig H; Pietschmann H
    Acta Med Austriaca; 1979; 6(5):255-60. PubMed ID: 555224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
    Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M
    Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of thalidomide in previously untreated patients with multiple myeloma.
    Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 6. Current concepts in cancer. Multiple myeloma.
    McIntyre OR
    N Engl J Med; 1979 Jul; 301(4):193-6. PubMed ID: 377077
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple myeloma: results with the M-2 protocol in a community hospital.
    Miller S; Perrotta AL
    J Am Osteopath Assoc; 1979 Aug; 78(12):857-64. PubMed ID: 489428
    [No Abstract]   [Full Text] [Related]  

  • 8. [Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
    Bataille R; Morlock G; Rosenberg F; Lopitaux R; Blotman F; Sany J; Ciurana AJ; Rampon S; Bussière JL; Simon L; Serre H
    Rev Rhum Mal Osteoartic; 1980 Feb; 47(2):77-82. PubMed ID: 7361063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Primary treatment results in myeloma disease using a cytostatic preparation].
    Iavorkovskiĭ LI; Soloveĭ DIa; Udris OIu; Riauzova LIu; Bliumental' RIa
    Probl Gematol Pereliv Krovi; 1981 Aug; 26(8):36-40. PubMed ID: 7301789
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical study on chemotherapy for multiple myeloma. Part III: The disappearance of M-protein in multiple myeloma].
    Adachi T; Hasegawa M; Asano K; Sezaki T; Ishii H; Takahashi I; Kimura I
    Rinsho Ketsueki; 1983 Apr; 24(4):440-7. PubMed ID: 6887544
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapy of paraproteinemic hemoblastoses].
    Fereberger W
    Acta Med Austriaca; 1982; 9(4):151-7. PubMed ID: 6814158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Determination of the tumor cell mass and its significance as a parameter for prognosis and therapy in patients with multiple myeloma].
    Ludwig H; Schneider K; Pietschmann H
    Acta Med Austriaca; 1978; 5(4-5):164-6. PubMed ID: 756132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
    Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.
    Palumbo A; Triolo S; Baldini L; Callea V; Capaldi A; De Stefano V; Grasso M; Liberati M; Lotesoriere C; Marcenò R; Marmont F; Musto P; Petrucci MT; Spriano M; Pileri A; Boccadoro M
    Haematologica; 2000 May; 85(5):508-13. PubMed ID: 10800168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study on chemotherapy for multiple myeloma. Part II: Prognostic factors of treatment with prednisolone and sequential melphalan and ifosfamide: MIP therapy].
    Sezaki T; Ishii H; Adachi T; Takahashi I; Ohnoshi T; Kimura I
    Rinsho Ketsueki; 1983 Apr; 24(4):433-9. PubMed ID: 6887543
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chemotherapy of multiple myeloma. Review of the recent trials].
    Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A
    Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical study on the chemotherapy of multiple myeloma. 1. Therapeutic effect of sequential combination therapy using melphalan, ifosfamide, and prednisolone].
    Sezaki T; Ishii H; Osada T; Adachi T; Takahashi I; Ohnoshi T; Kimura I
    Rinsho Ketsueki; 1982 Jun; 23(6):847-53. PubMed ID: 7176091
    [No Abstract]   [Full Text] [Related]  

  • 18. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
    Fenk R; Schneider P; Kropff M; Huenerlituerkoglu AN; Steidl U; Aul C; Hildebrandt B; Haas R; Heyll A; Kobbe G;
    Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
    Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.